Investors - Media Releases

Stay Informed

2010 2009 2008 2007 2006 2005 2004 2003

Back to list

January 14, 2010

Mondobiotech is inventions patent champion in 2009

Stans, Switzerland - January 14, 2010 - mondoBIOTECH holding AG (SIX: RARE), the Swiss biotech company finding therapies for rare diseases announced today a global top ranking position in patent inventions for the year 2009. A report by Thompson Reuters, which highlights twelve key technology areas in 2009 as well as the level of global innovation in each technology, was published by BusinessWeek http://www.businessweek.com on 10th January 2010. BusinessWeek there classifies Mondobiotech as the winner in the category pharmaceutical industry. Based on The Derwent World Patents Index (DWPI) database from Thomson Reuters, which consolidates the respective ?gures from 41 major patent issuing authorities worldwide, Mondobiotech in 2009 came in first rank among the pharmaceutical industry. “We are thrilled by this result” said Fabio Cavalli, CEO, Founder, and Member of the Board of Directors of mondoBIOTECH holding AG. “It demonstrates and validates again the power and the ability of our innovative, internet and scientific community based research approach”. “The power of our search & match approach is a fantastic proven way for patentable innovations”, commented Dorian Bevec, Chief Scientific Officer of mondoBIOTECH holding AG “We are opening new opportunities for the outlicencing of our products. By continuously doing so, we will constantly increase the pipeline of medicinal product candidates for rare diseases. This shows that we are able to be the biggest discoverer of novel drugs in the world for pharma, biotech, patient associations, or anybody else interested and committed to improving the status of the affected patients”. About Mondobiotech Mondobiotech (mondoBIOTECH holding AG: SIX: RARE), an independent, internet-based biotech research company, discovers drugs for patients suffering from rare and neglected diseases. Mondobiotech has built a continuously growing global community of biologists, biochemists, physicians, patients and patient advocacy organizations who share their passion and skills with Mondobiotech. Together with Mondobiotech, this community is searching for treatments for rare and neglected diseases. For further information please contact: mondoBIOTECH holding AG Dr. Yvonne Gunsch-Wegmann, MBA Head of External Relations Mürgstrasse 18 CH-6370 Stans Tel.: +41 (0) 840 200 010 Fax: +41 (0) 840 200 011 media@mondobiotech.com www.mondobiotech.com Sources http://www.businessweek.com/innovate/next/archives/2010/01/who_are_the_pat.html PDF Thomson Reuters 2009 Innovation Report Disclaimer The foregoing release may contain forward-looking statements. The words  “anticipates”, “believes”, “estimates”, “expects”, “intends”, “may”,  “plans”,  “projects”,  “will”,  “would”  and  similar expressions  are intended  to  identify forward-looking statements, although not  all forward-looking statements contain these identifying words.   mondoBIOTECH holding AG may not achieve the plans, intentions or expectations disclosed in its forward-looking statements and prospective investors should not place reliance on mondoBIOTECH holding AG’s forward looking statements. There can be no assurance that results of the activities and results of operations will not differ materially from the expectations. Forward- looking statements are subject to inherent risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by or underlying the forward looking statements. mondoBIOTECH holding AG is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. Personal Information This email is from mondoBIOTECH holding AG. The email and any files transmitted with it are intended solely for the use of the individual or entity to which they are addressed. Any unauthorized dissemination or copying of this email or its attachments, is strictly prohibited and may be illegal. If you have received the email in error please delete it from your system. Download the Newsletter in pdf format

Back to list